Abstract: The majority of patients with thyroid cancer can attain a favorable prognosis following surgery; however, this is not the case for advanced thyroid cancer. Chimeric antigen receptor T-cell (CAR-T) immunotherapy has demonstrated successful outcomes in hematological tumors. Building upon this success, researchers have explored the application of CAR-T therapy in solid tumors, yet the results have been less than optimal. Although research into CAR-T for advanced thyroid cancer is underway, it remains primarily in the realm of basic research, with limited clinical trials and inconclusive outcomes. In this review, we examine pertinent reports to offer insights for future research endeavors.